Blue Jet Healthcare Limited

Blue Jet Healthcare Limited is a specialty pharmaceutical ingredient and healthcare intermediate manufacturer based in Maharashtra, India. Originally incorporated in 1968 as Jet Chemicals Private Limited in Mumbai, the company was the first Indian manufacturer of saccharin and its salts, artificial sweeteners used widely across the food and beverage industry. Over the decades it broadened its product portfolio into contrast media intermediates, key inputs used in CT scan and MRI imaging agents, alongside a wider range of advanced pharmaceutical intermediates and active pharmaceutical ingredients. The company operates three manufacturing facilities in Maharashtra, located at Shahad, Ambernath and Mahad, supporting process development and commercial-scale production. It positions itself as a contract development and manufacturing partner, offering process development capability, global regulatory support and collaborative manufacturing arrangements to pharmaceutical and healthcare customers. As of September 2022 the company reported serving more than 350 customers spread across 35 countries. A large share of Blue Jet Healthcare's revenue, roughly four-fifths, is generated from customers in Europe and the United States, markets characterised by strict regulatory oversight for pharmaceutical ingredient suppliers. Its customer base is also fairly concentrated, with a small number of top accounts contributing a significant majority of revenue. The company's IPO consisted entirely of an offer for sale by its promoters and other selling shareholders, meaning the listing itself raised no fresh capital for the business.

The company raised approximately Rs 252 crore from anchor investors ahead of the issue, with allocations at the upper price band of Rs 346 per share. Notable anchor participants included Government Pension Fund Global, ICICI Prudential Mutual Fund, HDFC Mutual Fund and Nippon Life India.